CSI Market
Sign In | Register

Iovance Biotherapeutics inc (IOVA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access IOVA quarterly Cash Flow →
From Iovance Biotherapeutics inc through Dec 31 2021, changes in Dec 31 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-390.98
Depreciation & amortization12.86
Amortization of Other Assets23.08
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase-0.81
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.04
Share-based Compensation61.58
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total-0.24
Impairment Of Intangible Assets Excluding Goodwill-
Fair Value Of Derivative Liability Recorded Upon Issuance Of Warrants-
Private Placement Costs-
Increase Decrease In Fair Value Of Unhedged Derivative Instruments-
Fair Value Of Common Stock Transferred To Officer And Director-
Common Shares To Be Issued With12 Promissiory Notes-
Private Placement Costs-
Derivative Gain Loss On Derivative Net-
Fair Value Of Common Stock And Warrants Accounted For As Financing Costs-
Accrued Interest And Penalty-
Common Stock Issued To Induce Conversion Of Warrants-
Common Stock Issued To Induce Exchange Transaction-
Non Cash Lease Expense-
Gain Loss Related To Litigation Settlement-
Operating Lease Right Of Use Asset Amortization Expense-
Increase Decrease In Operating Lease Liability-10.90
Income taxes-2.07
Unrealized Gain (Loss) on Investments0.05
Increase (Decrease) in Accounts Receivable-13.11
Increase (Decrease) in Accounts Payable-6.66
Increase (Decrease) in Accrued Liabilities28.64
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-8.02
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities4.13
Discontinued operations0.00
Net Cash flow from Operating Activities-302.41
Investing Activities
Capital Expenditures-33.84
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities400.00
Payments to Acquire Available-for-sale Securities, Debt-318.67
Real Estate Investments0.00
Payments Of Contingent Consideration For Asset Acquisition-
Payments For Asset Acquisition Including Contingent Consideration Net Of Cash Acquired-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities47.50
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock306.32
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-7.06
Proceeds From Issuance Of Secured Promissory Notes Net-
Proceeds From Issuance Of Common Stock Upon Conversion Of Warrants-
Proceeds From Issuance Of Common And Preferred Stock-
Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan1.51
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities300.77
Effect of exchange rate on cash flow1.14
Discontinued operations0.00
Free Cash Flow-336.24
Total Cash Flow47.01
4 historic quarters locked

Sign in to unlock the full Iovance Biotherapeutics inc cash flow history.

Sign In Create Free Account

About Iovance Biotherapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-018899

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License